|
Market Cap (17-May) $1,668,273,536 (454th) |
Close (30-Jun) $12.25 |
Volume (30-Jun) 261,029 |
Shortsold (5-May) 7,255,072 (5.76%) (39th) |
|
52w High $24.00 |
52w Low $8.61 |
P/E 76.34 |
EPS 1.09 |
NEU released this announcement to the ASX on 25 February 2022, 9:31. The announcement is marked as price sensitive, and is 2 page(s) in length and 154.3kb in size.
You can view all announcements from NEU and see how they appear on a price chart on the announcements page.
At the date of this announcement, NEU was 0.000% short sold according to ASIC data. It was ranked the 676th most shorted stock on the ASX. It is now ranked as the 39th most shorted stock on the ASX with 5.756% of total shares short sold as of the latest reported data (05 May 2025).
| Other Recent Announcements from NEU | |
|---|---|
| Neuren completes enrolment in Phelan-McDermid Phase 2 trial | 30 June 2023, 9:36 |
| Neuren opens first site in US for Prader-Willi Phase 2 trial | 28 June 2023, 9:55 |
| Change of Director's Interest Notice | 14 June 2023, 18:44 |
| FDA approval for Angelman IND and Phase 2 trial | 25 February 2022, 9:31 |
| 2021 Results - a transformational year for Neuren | 24 February 2022, 9:36 |
| Preliminary Final Report and 2021 Full Year Accounts | 24 February 2022, 9:31 |
| Notification regarding unquoted securities - NEU | 3 February 2022, 17:02 |
You must be logged in to post a reply.
Neuren Pharmaceuticals 